Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
AZD0120 vs Standard Therapy in NDMM Patients Ineligible for ASCT (DURGA-5)
NCT07764978Phase 3Recruiting
- Sponsor
- AstraZeneca
- Start
- Jun 2026
- Primary completion
- Jan 2029
- Countries
- 15
01
Overview
Phase 3, randomised, open-label trial of GC012 in multiple myeloma (MM) (2 arms), sponsored by AstraZeneca. Primary endpoints: Progression-Free Survival up to 9 years and Minimal Residual Disease negative Complete Response rate at 9 months. Started Jun 2026; status: recruiting.
02
Drugs
GC012
03
Conditions
multiple myeloma (MM)
Beyond the preview
Go deeper on NCT07764978.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07764978.